AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34908536
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (up to a serum level of 0.8‐1.5 mEq/L)
Trial: 32381151
Drug: VC injection
RxNorm normalized name: phenylephrine hydrochloride / promethazine hydrochloride Oral Solution [Phenergan VC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC injection pre-transit (5 g sodium ascorbate/steer)
Trial: 32381151
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection pre-transit and VC injection post-transit
Trial: 32381151
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection pre- and post-transit (CON)
Trial: 34437978
Drug: Mast-cell inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mast-cell inhibitors
Trial: 35305596
Drug: Dacomitinib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib (45 mg/day)
Trial: 32142084
Drug: 1 gram
RxNorm normalized name: guar gum 1 gram ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram of pure eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), or docosahexaenoic acid (DHA) daily for 6 days
Trial: 36414937
Drug: Supplementary suckling
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary suckling technique with high or low protein milk-based formula supplement
Trial: 36463226
Drug: CC-486 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (300 mg daily on days 1-21 of a 28-day cycle)
Trial: 32364091
Drug: Casein protein
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein protein (CP) 25 g
Trial: 33159632
Drug: Pediatric Autism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric Autism Spectrum Therapy Observation System (PASTOS)
Trial: 33159632
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (manual-based)
Trial: 34606846
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Trial: 616996904
Drug: Bisoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (10 mg)
Trial: 32513936
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT), 40 IU, administered as a single acute dose over 18–26 min post dosing.
Trial: 32513936
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered as a control treatment.
Trial: 35253516
Drug: 50 µg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg LSD
Trial: 35253516
Drug: 75 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 µg LSD
Trial: 35253516
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg LSD
Trial: 35253516
Drug: 50 µg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg followed by 75 µg LSD (1 week apart)
Trial: 35253516
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by 75 µg LSD (1 week apart)
Trial: 32307626
Drug: Poor oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor oral health knowledge, high dental anxiety, brushing teeth less than once a day, and regular consumption of chocolates or biscuits.
Trial: 33402037
Drug: Any antithrombotic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any antithrombotic therapy
Trial: 33649451
Drug: No bladder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bladder antimuscarinic treatment (control group).
Trial: 32909511
Drug: Trimetazidine (TMZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ), 20 mg thrice daily orally 24 hours before and 72 hours after PCI
Trial: 39454963
Drug: Metacognitive Interpersonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive Interpersonal Therapy (MIT)
Trial: 35221673
Drug: Tadalafil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (5 mg) alone
Trial: 35221673
Drug: Amlodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (10 mg) alone
Trial: 35221673
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of tadalafil and amlodipine
Trial: 32128907
Drug: Topical rapamycin
RxNorm normalized name: natamycin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rapamycin solution (1 mg/mL) applied twice daily for 3 months
Trial: 32128907
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate ointment 0.05% in Orabase® applied twice daily for 3 months
Trial: 32460815
Drug: Defining a
RxNorm normalized name: refined almond oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defining a minimum expertise level for treatment provider
Trial: 36088327
Drug: sST2 ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sST2 ≥ 32.0 ng/mL
Trial: 36088327
Drug: sST2 16.5–32.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sST2 16.5–32.0 ng/mL
Trial: 36088327
Drug: NT-proBNP ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP ≥ 337 ng/L
Trial: 36088327
Drug: NT-proBNP 89–337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP 89–337 ng/L
Trial: 36088327
Drug: hs-cTnI ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnI ≥ 7.8 ng/L
Trial: 35683592
Drug: Cell therapy
RxNorm normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell therapy
Trial: 35143411
Drug: 500 mg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/L buffered MS‐222 for 15 minutes
Trial: 35143411
Drug: 1000 mg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/L buffered MS‐222 for 15 minutes
Trial: 35143411
Drug: 1000 mg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/L buffered MS‐222 for 15 minutes, then placed in freshwater for 3 hours
Trial: 35143411
Drug: 1000 mg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/L buffered MS‐222 for 15 minutes, then placed in freshwater for 18 hours
Trial: 35143411
Drug: 1000 mg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/L buffered MS‐222 for 60 minutes, then placed in freshwater for 3 hours
Trial: 35285282
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention (ten 1-hour sessions, twice weekly)
Trial: 32861841
Drug: Family-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused therapy
Trial: 32421353
Drug: Intrapleural fibrinolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural fibrinolytic therapy (IPFT)
Trial: 32014032
Drug: S44819 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S44819 150 mg bid
Trial: 32014032
Drug: S44819 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S44819 300 mg bid
Trial: 32969391
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate intranasal spray
Trial: 36054369
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride intranasal spray (placebo)
Trial: 33508918
Drug: nCRT (XELOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCRT (XELOX chemotherapy: capecitabine + oxaliplatin) with concurrent radiotherapy (45 Gy, 25 times, 1.8 Gy/d, 5 times/week)
Trial: 33508918
Drug: nCRT (XELOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCRT (XELOX chemotherapy: capecitabine + oxaliplatin)
Trial: 36115523
Drug: Deucravacitinib 6
RxNorm normalized name: deucravacitinib 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib 6 mg daily
Trial: 34639109
Drug: Vaginal injection
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal injection of recombinant human follicle-stimulating hormone (rhFSH)
Trial: 34639109
Drug: Abdominal injection
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal injection of recombinant human follicle-stimulating hormone (rhFSH)
Trial: 34639109
Drug: Daily abdominal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily abdominal or vaginal injections of rhFSH (1 IU twice daily for 4 days)
Trial: 34639109
Drug: Intermittent vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent vaginal injections of rhFSH (4 IU every other day for two doses)
Trial: 34639109
Drug: Intermittent abdominal
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent abdominal or vaginal injections of rhFSH
Trial: 34285426
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg bevacizumab and 1 mg intravitreal triamcinolone (combined treatment)
Trial: 34029235
Drug: Eccentric exercises
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric exercises with extracorporeal shockwave therapy (SWT group)
Trial: 34029235
Drug: Eccentric exercises
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric exercises with sham shockwave therapy (control group)
Trial: 34301749
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice chemotherapy (PC)
Trial: 32186523
Drug: Desoximetasone spray
RxNorm normalized name: desoximetasone Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desoximetasone spray 0.25% for 2 weeks with twice-daily telephone call reminders
Trial: 32186523
Drug: Desoximetasone spray
RxNorm normalized name: desoximetasone Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desoximetasone spray 0.25% for 2 weeks without reminders
Trial: 35813434
Drug: Transesophageal ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transesophageal ultrasound monitoring using ONLM algorithm with optimal pulmonary compliance titration of PEEP.
Trial: 33070176
Drug: Isoniazid AUC
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid AUC >21.78 mg · h/L
Trial: 33070176
Drug: Rifampicin AUC
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin AUC >82.01 mg · h/L
Trial: 35785423
Drug: Hard splint
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard splint therapy
Trial: 35785423
Drug: Soft splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft splint therapy
Trial: 33434035
Drug: Conidia suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conidia suspension with a concentration of 5×10^5/ml sprayed on fruits; maintained high humidity for 3 days
Trial: 33252568
Drug: OA-CXL (accelerated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OA-CXL (accelerated CXL with systemic oxygen at 5 L/min for 10 minutes)
Trial: 35014128
Drug: Echocardiography-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echocardiography-guided therapy with spironolactone
Trial: 33351921
Drug: Lifestyle therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle therapy plus testosterone (LT+Test)
Trial: 33351921
Drug: Lifestyle therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle therapy plus placebo (LT+Pbo)
Trial: 32436455
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily plus ASA 100 mg
Trial: 32436455
Drug: ASA 100
RxNorm normalized name: ASA 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 100 mg
Trial: 38748321
Drug: Lemborexant 5
RxNorm normalized name: lemborexant 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant 5 mg (LEM5)
Trial: 38748321
Drug: Lemborexant 10
RxNorm normalized name: lemborexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant 10 mg (LEM10)
Trial: 32682347
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg melatonin taken 1 hour before desired bedtime for 4 weeks (5-7 nights/week)
Trial: 34420834
Drug: Zonisamide 25
RxNorm normalized name: zonisamide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 25 mg/day
Trial: 32898787
Drug: Calorie-restricted diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calorie-restricted diet plus 109 CFU synbiotic supplement (CRS group; n = 45)
Trial: 35715184
Drug: Elagolix 200
RxNorm normalized name: elagolix 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix 200 mg two times per day for 8 weeks
Trial: 32677855
Drug: Warfarin dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin dosing algorithm for patients older than 60
Trial: 34126419
Drug: Shenhuang Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenhuang Granule (SHG) administered twice a day for 14 days
Trial: 33657757
Drug: Suit therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suit therapy
Trial: 34424546
Drug: rhGH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH therapy
Trial: 32946574
Drug: SJX-653 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJX-653 30 mg
Trial: 32946574
Drug: SJX-653 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJX-653 60 mg
Trial: 33393484
Drug: Mindfulness meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness meditation (MM) for 3 weeks, 45-minute daily sessions
Trial: 33128696
Drug: Disease-modifying anti-rheumatic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents
Trial: 32456874
Drug: Gelatin sponge
RxNorm normalized name: ABSORBABLE GELATIN SPONGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin sponge patch
Trial: 33004472
Drug: empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: empagliflozin (25 mg)
Trial: 33004472
Drug: LY2409021 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2409021 (300 mg)
Trial: 35143872
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 5 mg/kg solution every two days by gavage for two weeks
Trial: 35143872
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional treatments)
Trial: 35143872
Drug: Model group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model group (D-gal 500 mg/kg intraperitoneal injection every two days for six weeks)
Trial: 34396584
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL lidocaine (2%)
Trial: 36050587
Drug: Online group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online group problem-solving therapy (PST)
Trial: 36049147
Drug: encorafenib (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: encorafenib (450 mg orally once daily) plus binimetinib (45 mg orally twice daily) until progressive disease -> ipilimumab plus nivolumab (ipilimumab 3 mg/kg once every 3 weeks and nivolumab 1 mg/kg once every 3 weeks × four cycles -> nivolumab 3 mg/kg every 2 weeks)
Trial: 33357217
Drug: Edoxaban (a
RxNorm normalized name: edoxaban (as tosylate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (a direct oral anticoagulant)
Trial: 32636043
Drug: Early mobilization
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early mobilization (E-MOB) with a removable orthosis and daily wrist exercises
Trial: 32636043
Drug: Late mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late mobilization (L-MOB) with a standard dorsal plaster cast for 2 weeks followed by a removable orthosis and exercises
Trial: 32636043
Drug: Late mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late mobilization (L-MOB)
Trial: 35016497
Drug: TRLB (0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRLB (0.25% bupivacaine 0.4 ml/kg)
Trial: 36386982
Drug: Risperidone treatment
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone treatment for 12 weeks
Trial: 32078147
Drug: Intramuscular clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular clodronate 200 mg daily for 15 days and then once weekly for the next 11.5 months
Trial: 32078147
Drug: Intramuscular clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular clodronate 200 mg daily for 15 days and then once weekly for the next 2.5 months
Trial: 33373914
Drug: Placebo (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P) inhalation
Trial: 34325886
Drug: MitraClip plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitraClip plus guideline-directed medical therapy (GDMT)
Trial: 32313032
Drug: MR stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR stimulation (0.4 mg fludrocortisone)
Trial: 35717867
Drug: NMDA-R stimulation
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMDA-R stimulation (250 mg D-cycloserine)
Trial: 33963372
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg per day)
Trial: 33963372
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure lowering treatment
Trial: 32628547
Drug: Morphine Treatment
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine Treatment with Metoclopramide Coadministration
Trial: 32628547
Drug: Morphine Treatment
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine Treatment without Metoclopramide Coadministration
Trial: 33804824
Drug: Vaccine IBV
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine IBV strains
Trial: 37596449
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial: 36455453
Drug: PEA‐LUT 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEA‐LUT 700 mg + 70 mg
Trial: 34992123
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of venous leg ulcers with community staff involvement
Trial: 34399166
Drug: eNose analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eNose analysis for early monitoring during anti-PD-1 therapy
Trial: 33750646
Drug: SPN-812 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-812 200 mg
Trial: 33750646
Drug: SPN-812 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-812 400 mg
Trial: 33846037
Drug: Elevated CEA
RxNorm normalized name: Ad-CEA vaccine
DrugBank: Ad-CEA vaccine (DB17581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated CEA levels before treatment
Trial: 32692247
Drug: Whole brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole brain radiotherapy (WBRT) alone 300 cGy/fraction ×10 fractions, total dose 3,000 cGy
Trial: 32692247
Drug: Whole brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole brain radiotherapy (WBRT) alone 180 cGy/fraction ×22 fractions, total dose 3,960 cGy
Trial: 32692247
Drug: Intracranial metastases
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracranial metastases radiotherapy alone 250 cGy/fraction ×22 fractions, total dose 5,500 cGy
Trial: 32692247
Drug: Whole brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole brain + intracranial metastases group (SIB) whole brain 180 cGy/fraction ×22 fractions, intracranial metastases 250 cGy/fraction ×22 fractions, total doses 3,960 cGy and 5,500 cGy respectively
Trial: 34052007
Drug: Ivermectin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (0.2 mg/kg single dose)
Trial: 34912021
Drug: Split tablet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split tablet regimen (group S)